Rosana Correa Silva Azevedo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rosana Correa Silva Azevedo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ana Luiza Lunardi Rocha
Federal University of Minas Gerais Belo Horizonte Brazil
2 shared publications - Ana Lúcia Cândido
Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
2 shared publications - Fernando Marcos dos Reis
Department of Obstetrics and Gynecology Universidade Federal de Minas Gerais Belo Horizonte Brazil
2 shared publications - Luciana Costa Faria
Universidade Federal de Minas Gerais
2 shared publications - Claudia Alves Couto
Instituto Alfa de Gastroenterologia, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
1 shared publication - Daniela Oliveira de Lima Taranto
Univ Fed Minas Gerais, Posgrad Ciencias Aplicadas Saude Adulto, Belo Horizonte, MG, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (3) , 1-5
Dissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome
Introduction: Oxyntomodulin (OXM) is a polypeptide hormone of the incretin family, which binds to the glucagon-like peptide 1 receptor, contributing to a reduction in caloric intake, an increase in energy expenditure, and weight loss in obese individuals. Polycystic ovary syndrome (PCOS) is a multifactorial condition characterized by reproductive and metabolic dysfunctions, with a high prevalence among overweight and obese women. This study aimed to investigate the correlation between clinical, anthropometric, endocrine, and metabolic variables and plasma OXM levels in [...] ABSTRACT Introduction: Oxyntomodulin (OXM) is a polypeptide hormone of the incretin family, which binds to the glucagon-like peptide 1 receptor, contributing to a reduction in caloric intake, an increase in energy expenditure, and weight loss in obese individuals. Polycystic ovary syndrome (PCOS) is a multifactorial condition characterized by reproductive and metabolic dysfunctions, with a high prevalence among overweight and obese women. This study aimed to investigate the correlation between clinical, anthropometric, endocrine, and metabolic variables and plasma OXM levels in
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (3) , 1-5
Open AccessDissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome
Introduction: Oxyntomodulin (OXM) is a polypeptide hormone of the incretin family, which binds to the glucagon-like peptide 1 receptor, contributing to a reduction in caloric intake, an increase in energy expenditure, and weight loss in obese individuals. Polycystic ovary syndrome (PCOS) is a multifactorial condition characterized by reproductive and metabolic dysfunctions, with a high prevalence among overweight and obese women. This study aimed to investigate the correlation between clinical, anthropometric, endocrine, and metabolic variables and plasma OXM levels in [...] ABSTRACT Introduction: Oxyntomodulin (OXM) is a polypeptide hormone of the incretin family, which binds to the glucagon-like peptide 1 receptor, contributing to a reduction in caloric intake, an increase in energy expenditure, and weight loss in obese individuals. Polycystic ovary syndrome (PCOS) is a multifactorial condition characterized by reproductive and metabolic dysfunctions, with a high prevalence among overweight and obese women. This study aimed to investigate the correlation between clinical, anthropometric, endocrine, and metabolic variables and plasma OXM levels in
- Open Access
- 5 June 2020
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (3) , 235-242
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center
Polycystic ovary syndrome (PCOS) is a recognized risk factor for nonalcoholic fatty liver disease (NAFLD). The aims of this study were to investigate the prevalence and factors associated with NAFLD in women with PCOS and evaluate noninvasive indices of hepatic fibrosis in patients with PCOS and NAFLD. Patients with PCOS (n = 87) and women without PCOS (n = 40; controls) were included. NAFLD was diagnosed by abdominal ultrasonography after exclusion of alcohol consumption and viral or autoimmune liver disease. Anthropometric, clinical and metabolic variables, homeostasis model assessment of insulin resistance (HOMA-IR) index, lipid accumulation product (LAP), FIB-4 index, NAFLD score, and transient elastography (TE; FibroScan) were obtained in subsets of patients with PCOS and NAFLD. A total of 87 patients with PCOS were included (mean age: 34.4 ± 5.7 years, mean body mass index [BMI]: 34.7 ± 4.7 kg/m 2 ). NAFLD was present in 67 (77.0%) patients with PCOS versus 21 of 40 (52.5%) controls (p = 0.005). Women with PCOS and liver steatosis, compared with their NAFLD-free counterparts, had higher values of BMI, waist circumference, triglycerides, total cholesterol, alanine and aspartate aminotransferases, and γ-glutamyltransferase, along with higher frequencies of obesity, metabolic syndrome, and insulin resistance. NAFLD was independently associated with waist circumference, serum triglycerides, and alanine aminotransferase levels. The FIB-4 index was not compatible with advanced fibrosis in any of the evaluated patients, while NAFLD score and TE were compatible with advanced liver fibrosis in 1 of 26 (3.8%) and 3 of 25 (12%) patients, respectively. Women with PCOS had a high risk of NAFLD, and a combination of both was associated with central obesity, dyslipidemia, insulin resistance, and metabolic syndrome. Noninvasive methods suggested low rates of severe hepatic fibrosis in Brazilian women with PCOS. Arch Endocrinol Metab. 2020;64(3):235-42.
- 5 June 2020
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (3) , 235-242
Open AccessNonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center
Polycystic ovary syndrome (PCOS) is a recognized risk factor for nonalcoholic fatty liver disease (NAFLD). The aims of this study were to investigate the prevalence and factors associated with NAFLD in women with PCOS and evaluate noninvasive indices of hepatic fibrosis in patients with PCOS and NAFLD. Patients with PCOS (n = 87) and women without PCOS (n = 40; controls) were included. NAFLD was diagnosed by abdominal ultrasonography after exclusion of alcohol consumption and viral or autoimmune liver disease. Anthropometric, clinical and metabolic variables, homeostasis model assessment of insulin resistance (HOMA-IR) index, lipid accumulation product (LAP), FIB-4 index, NAFLD score, and transient elastography (TE; FibroScan) were obtained in subsets of patients with PCOS and NAFLD. A total of 87 patients with PCOS were included (mean age: 34.4 ± 5.7 years, mean body mass index [BMI]: 34.7 ± 4.7 kg/m 2 ). NAFLD was present in 67 (77.0%) patients with PCOS versus 21 of 40 (52.5%) controls (p = 0.005). Women with PCOS and liver steatosis, compared with their NAFLD-free counterparts, had higher values of BMI, waist circumference, triglycerides, total cholesterol, alanine and aspartate aminotransferases, and γ-glutamyltransferase, along with higher frequencies of obesity, metabolic syndrome, and insulin resistance. NAFLD was independently associated with waist circumference, serum triglycerides, and alanine aminotransferase levels. The FIB-4 index was not compatible with advanced fibrosis in any of the evaluated patients, while NAFLD score and TE were compatible with advanced liver fibrosis in 1 of 26 (3.8%) and 3 of 25 (12%) patients, respectively. Women with PCOS had a high risk of NAFLD, and a combination of both was associated with central obesity, dyslipidemia, insulin resistance, and metabolic syndrome. Noninvasive methods suggested low rates of severe hepatic fibrosis in Brazilian women with PCOS. Arch Endocrinol Metab. 2020;64(3):235-42.
Laryngeal histoplasmosis in an immunocompetent patient from a non‐endemic region: case report
Histoplasma capsulatum infection involving the larynx is a rare manifestation, especially in immunocompetent individuals and a high index of suspicion is needed to establish the diagnosis correctly. We report a case of a 50‐year‐old Brazilian man who presented with progressive hoarseness and throat pain for 4 months. Laryngoscopy showed a supraglottic vegetant lesion, and the biopsies chronic granulomatous inflammation without any specific agent. A second laryngoscopy with biopsies was performed and after 17 days of incubation in specific medium, H. capsulatum was isolated. The patient was successfully treated with amphotericin B.
Laryngeal histoplasmosis in an immunocompetent patient from a non‐endemic region: case report
Histoplasma capsulatum infection involving the larynx is a rare manifestation, especially in immunocompetent individuals and a high index of suspicion is needed to establish the diagnosis correctly. We report a case of a 50‐year‐old Brazilian man who presented with progressive hoarseness and throat pain for 4 months. Laryngoscopy showed a supraglottic vegetant lesion, and the biopsies chronic granulomatous inflammation without any specific agent. A second laryngoscopy with biopsies was performed and after 17 days of incubation in specific medium, H. capsulatum was isolated. The patient was successfully treated with amphotericin B.